^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
diethyl dihydroxyhomospermine (SBP-101)
i
Other names: SBP-101, SB17170, SB-17170, SB 17170, SBP101, SBP 101
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Handok, SPARK BioPharma
Drug class:
HMGB1 inhibitor, MDSC modulator
Related drugs:
8ms
SB17170 Phase1 Trial in Healthy Volunteer (clinicaltrials.gov)
P1, N=64, Completed, SPARK Biopharma | Recruiting --> Completed
Trial completion
|
diethyl dihydroxyhomospermine (SBP-101)
1year
SB17170 Phase 1 Clinical Trial in Solid Tumors (clinicaltrials.gov)
P1, N=50, Recruiting, SPARK Biopharma | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jan 2024 --> Dec 2024
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • S100A8 (S100 Calcium Binding Protein A8) • S100A9 (S100 Calcium Binding Protein A9) • HMGB1 (High Mobility Group Box 1)
|
diethyl dihydroxyhomospermine (SBP-101)
2years
SB17170 Phase 1 Clinical Trial in Solid Tumors (clinicaltrials.gov)
P1, N=50, Recruiting, SPARK Biopharma | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
PD-L1 (Programmed death ligand 1) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • S100A8 (S100 Calcium Binding Protein A8) • S100A9 (S100 Calcium Binding Protein A9) • HMGB1 (High Mobility Group Box 1)
|
diethyl dihydroxyhomospermine (SBP-101)
2years
SB17170 Phase 1 Clinical Trial in Solid Tumors (clinicaltrials.gov)
P1, N=50, Not yet recruiting, SPARK Biopharma
New P1 trial
|
PD-L1 (Programmed death ligand 1) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • S100A8 (S100 Calcium Binding Protein A8) • S100A9 (S100 Calcium Binding Protein A9) • HMGB1 (High Mobility Group Box 1)
|
diethyl dihydroxyhomospermine (SBP-101)
Share via
